M-Audio produces MIDI controllers and audio interfaces, offering products similar to Nektar's GXP series.

M-Audio

Alesis is a manufacturer of electronic musical instruments, including MIDI controllers, with products comparable to Nektar's offerings.

Alesis

Panorama offers advanced channel strip and plugin controllers, including models compatible with various DAWs, competing with Nektar's products.

Panorama

Nektar Technology is a music technology company that designs and manufactures innovative MIDI controllers, keyboard controllers, and software for music production and performance.

Nektar Technology, Inc.

Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and viral diseases. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates.

Pearl Therapeutics

Deerfield

SFJ Pharmaceuticals

AstraZeneca

New Enterprise Associates

Nektar Therapeutics

At #JPM2024 next week, Nektar’s management team will present on exciting company updates across our #immunology and #immunooncology pipelines. Learn more about us: https://bit.ly/47nZHVe

New preclinical data presented at #ASH23 by our collaborators at NYMC highlight that NKTR-255, in combination with obinutuzumab, expanded NK cells and enhanced antibody-dependent cellular cytotoxicity against rituximab-resistant Burkitt lymphoma cells. Learn more: https://bit.ly/48fE3DO

We’re celebrating Mary Tagliaferri, MD, Nektar’s Chief Medical Officer, who was recently named as one of Inc. Magazine’s 10 Most Eminent Women Leaders in Healthcare 2023. Learn more about Mary and the vital role she plays at Nektar directing clinical strategy, operations and medical affairs: https://bit.ly/3smei5l

At #EADVCongress this week, we presented new and encouraging responder data in late-breaking news oral presentation for Rezpegaldesleukin, our first-in-class selective T-reg therapy, in patients with #atopicdermatitis, also being studied in #alopeciaareata. Full press release: https://bit.ly/3M1sIye

We’re gearing up for #EADVCongress next week, where Nektar will have two presentations for Rezpegaldesleukin, our first-in-class selective regulatory T-cell therapy, being studied in #atopicdermatitis and #alopeciaareata. Additional details: https://bit.ly/3ZDSoXx

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Feb 21, 2024 5:08 PM	e285129d
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 21, 2024 5:08 PM	16eb663b
company summary	general
signals	general
crunchbase trigger	general	Nov 12, 2024 12:52 PM	8b277b03
crunchbase profile	general
li profile	general
translate crunchbase fundingrounds	general
peers	general	Feb 21, 2024 5:08 PM	00552530
news basic	general	Feb 21, 2024 5:08 PM	533bd5d3
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:NEKTARTECH

Nektar Therapeutics